WO2008014054A2 - Compositions à base de variantes de bmp-7, procédés et utilisations - Google Patents

Compositions à base de variantes de bmp-7, procédés et utilisations Download PDF

Info

Publication number
WO2008014054A2
WO2008014054A2 PCT/US2007/070584 US2007070584W WO2008014054A2 WO 2008014054 A2 WO2008014054 A2 WO 2008014054A2 US 2007070584 W US2007070584 W US 2007070584W WO 2008014054 A2 WO2008014054 A2 WO 2008014054A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nucleic acid
sequence shown
acid sequence
peptide chain
Prior art date
Application number
PCT/US2007/070584
Other languages
English (en)
Other versions
WO2008014054A3 (fr
Inventor
Bernard Amegadzie
Mark R. Cunningham
Haimanti Dorai
Jeffrey Luo
Juliane Mills
Bethany Swencki-Underwood
Original Assignee
Centocor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc. filed Critical Centocor, Inc.
Priority to JP2009521874A priority Critical patent/JP2009544325A/ja
Priority to EP07798210A priority patent/EP2056852A4/fr
Publication of WO2008014054A2 publication Critical patent/WO2008014054A2/fr
Publication of WO2008014054A3 publication Critical patent/WO2008014054A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to human Bone Morphogenic Protein 7 (hBMP-7) variant peptide chains, nucleic acid chains encoding these peptide chains, and methods of making and using the foregoing.
  • hBMP-7 human Bone Morphogenic Protein 7
  • hBMP-7 Human Bone Morphogenic Protein 7
  • TGF- ⁇ superfamily of proteins has recognized therapeutic potential as both a modulator of bone structure and renal function (Klahr, J. Nephrol. 16:179-185 (2003)).
  • active hBMP-7 could be used as a protein therapeutic in indications such as myelofibrosis, idiopathic pulmonary fibrosis, renal osteodystrophy, renal fibrosis, diabetic nephropathy, chronic obstructive pulmonary disorder (COPD) , and osteoarthritis .
  • COPD chronic obstructive pulmonary disorder
  • hBMP-7 is transcribed as mRNA containing a 1293 base pair open reading frame (the corresponding cDNA is shown at SEQ ID NO: 1) which is translated as a precursor protein of 431 amino acid residues (Fig 1; SEQ ID NO: 2) that is proteolytically processed.
  • the hBMP-7 precursor protein contains a signal peptide spanning residues 1 to 29 of SEQ ID NO: 2, a prodomain spanning residues 30-292 of SEQ ID NO: 2, and a mature form domain spanning residues 293-431 of SEQ ID NO: 2 (Fig. 1) .
  • Proteolytic processing of the hBMP-7 precursor protein is believed to occur in several steps.
  • the signal peptide directs hBMP-7 to the endoplasmic reticulum of the cell where folding occurs and hBMP-7 forms a homodimeric protein complex.
  • the hBMP-7 prodomain is removed by proteolytic processing to produce a covalently linked homodimer consisting of two antiparallel hBMP-7 mature domain peptide chains. This final homodimeric protein complex is the biologically active form and secreted by cells.
  • Secreted hBMP-7 interacts with surface receptors on other cells and soluble antagonists, such as ActRII, BMPRIa, and Noggin to mediate its biological effects and activity.
  • Structural information concerning these interactions can be derived from a number of different BMP-7 crystal structures (Greenwald et al . , MoI. Cell. 11:605-017 (2003); Griffith et al., PNAS. 93:878-883 (1996); Keller et al . , Nat. Struct. MoI. Biol. 5:481-488 (2004); Groppe et al . , Nature. 420 (6916) : 636-642 (2002) .
  • hBMP-7 (formerly known as osteogenic protein 1 (OP-I) by Ozkaynak et al . (EMBO J. 9(7), 2085-2093 (1990)) has been known at least since 1990, to date several unresolved problems have prevented its development as a therapeutic protein.
  • OP-I osteogenic protein 1
  • recombinant expression of hBMP-7 in mammalian cells is extremely low relative to other proteins of similar size. This is incompatible with the large-scale commercial production and purification needed for therapeutic use of hBMP- 7.
  • proteolytic processing of the mature domain of hBMP- 7 can occur at any of four different sites in that domain. This results in a number of different mature forms of hBMP-7 being produced during the recombinant expression of this protein.
  • hBMP-7 variant peptide chains with improved properties that are suitable for use as therapeutic proteins and are compatible with large-scale commercial production and purification.
  • Fig. 1 shows the wild-type hBMP-7 precursor amino acid sequence and hBMP-7 amino acid sequence feature map. Underlined bold text denotes the amino terminus of mature hBMP-7.
  • Fig. 2 shows expression of hBMP-7 variants encoded by p3104, p3105, p3106, p3107, and p3108 as assayed by sandwich- type ELISA.
  • Fig. 3 shows expression of hBMP-7 variants encoded by p3341, p3392, p3268, and p3470 as assayed by sandwich-type ELISA.
  • Fig. 4 shows biological activity of hBMP-7 variant 3392 (SEQ ID NO: 42) in a ROS 17/2.8 osteosarcoma cell-based assay system.
  • Fig. 5 shows biological activity of hBMP-7 variant 3392 (SEQ ID NO: 42) in a VEPT kidney cell proliferation-based assay system.
  • One aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 4.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 6.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 8.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 10.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 12.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 18.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 20.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 22.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 24.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 26.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 28.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 30.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 32.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 34.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 36.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 38.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 40.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 42.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 44.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 46.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 48.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 3.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 5.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 7.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 9. Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 11.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 13.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 15.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 17.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 19. Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 21. Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 23.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 25.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 27.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 29.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 31.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 33.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 35.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 37.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 39.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 41.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 43.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 45.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 47.
  • peptide chain means a molecule comprising at least two amino acid residues linked by a peptide bond to form a chain. Large peptide chains of more than 50 amino acids may be referred to as “polypeptides” or “proteins.” Small peptide chains of less than 50 amino acids may be referred to as “peptides. "
  • nucleic acid means a molecule comprising at least two nucleic acid residues linked to form a chain. Such nucleic acid residues may be those found in DNA or RNA. Small nucleic acids of less than 50 residues may be referred to as
  • oligonucleotides oligonucleotides .
  • the term "hBMP-7 responsive condition” means a pathological condition that is responsive to a biological activity of a hBMP-7 peptide chain or a hBMP-7 variant peptide chain. Such peptide chains may comprise a fragment of SEQ ID NO: 2 or a peptide chain of the invention.
  • Examples of hBMP-7 activity responsive pathological conditions include, for example, myelofibrosis, idiopathic pulmonary fibrosis, renal osteodystrophy, diabetic nephropathy, chronic obstructive pulmonary disorder (COPD), and osteoarthritis.
  • Biological activities resulting from hBMP-7 peptide chain or a hBMP-7 variant peptide chain include, for example, induction of bone formation, increased alkaline phosphatase activity, increased hyaluronan synthase 2 mRNA levels, increased type I collagen mRNA levels, increased osteocalcin synthesis, and inhibition of TGF- ⁇ induced cell proliferation.
  • Those skilled in the art will recognize many other such biological activities and pathological conditions .
  • the invention provides isolated peptide chain hBMP-7 variant compositions, nucleic acids encoding these compositions, and related methods.
  • the compositions and methods of the invention will be useful in controlling cell proliferation and in the treatment of hBMP-7 responsive conditions such as myelofibrosis, idiopathic pulmonary fibrosis, renal osteodystrophy, diabetic nephropathy, chronic obstructive pulmonary disorder (COPD), and osteoarthritis.
  • All peptide chains and nucleic acids of the invention were derived by mutagenesis using standard in vitro or in vivo methods, or combinations of such methods, from the cDNA (SEQ ID NO: 1) encoding the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2. All mutated positions in the hBMP-7 variant peptide chains of the invention are described herein by referencing the position of the amino acid residue that has been changed in the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2. Conventional one and three-letter amino acid codes are used herein as follows:
  • R299S denotes that the R (arginine) amino acid at position 299 of SEQ ID NO: 2 has been changed to an S (serine) amino acid
  • ⁇ S293-R299 indicates that the amino acid sequence starting at S amino acid at position 293 of SEQ ID NO: 2 and ending at the R at position 299 of SEQ ID NO: 2 has been deleted.
  • Wild-type hBMP-7 (SEQ ID NO: 2) has several important properties and features which may be modified by mutation. First, multiple mature hBMP-7 isoforms, each with different amino termini, can be produced during proteolytic processing of the hBMP-7 precursor protein (SEQ ID NO: 2).
  • the S293, R299S, R314S, ⁇ S293-R299, ⁇ S293-R314, and ⁇ S293-M315 mutations were each designed to prevent the formation of multiple mature hBMP-7 isoforms with different amino termini by eliminating cleavage in hBMP-7 variant peptide chains at the positions affected by each mutation.
  • the H287R and H287T mutations flank a core furin cleavage site located in the hBMP-7 prodomain of SEQ ID NO: 2.
  • the H287R and H287T mutations were both designed to enhance furin cleavage events that produce an amino terminus at S293 of SEQ ID NO: 2 in hBMP-7 variant peptide chains.
  • mature hBMP-7 forms complexes with the ActRII and BMPPRIa receptor proteins.
  • the L407K, F409K, L417R, L382K, L382N, V383K, I386R, and I386N mutations were designed to decrease the surface hydrophobicity of hBMP-7 variant peptide chains while at the same time minimizing any disruption to hBMP- 7 variant : ActRII or hBMP-7 variant : BMPPRIa peptide chain complex formation.
  • Such decreased surface hydrophobicity in hBMP-7 variant peptide chains is designed to reduce the formation of aggregates by variants containing these mutations while still permitting hBMP-7 mediated signaling through the ActRII and BMPPRIa receptor proteins.
  • mature hBMP-7 can be bound by the soluble antagonist protein Noggin.
  • the W347D mutation was designed to decrease hBMP-7 variant peptide chain binding to Noggin to enhance hBMP-7 mediated signaling and biological activity.
  • mutations at R421, N422, and R426 of hBMP-7 may increase expression of the resulting hBMP-7 variant peptide chain.
  • mutations such as R421E, N422D, and R426E improve hBMP-7 variant peptide chain expression by increasing the solubility of the expressed peptide chain.
  • the pharmacological properties of hBMP-7 variant peptide chains, such as in vivo half-life may be improved by pegylation.
  • the S293C mutation is designed to create an amino terminal C residue in the mature form of the hBMP-7 variant peptide chains containing this mutation. This amino terminal C residue can then be post-translationally modified by the covalent attachment of polyethylene glycol by techniques known to those skilled in the art.
  • Last, deletion and domain replacement mutants derived from the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2 can be designed to improve hBMP-7 variant peptide chain expression.
  • One such hBMP-7 variant peptide chain mutant comprises the hBMP- 7 signal peptide and prodomain alone, but lacks the hBMP-7 mature form domain which has been deleted.
  • Another such mutant comprises the human growth hormone signal peptide (residues Ml to A26 of SEQ ID NO: 38) which replaces the native hBMP-7 secretory signal peptide, lacks the hBMP-7 prodomain which has been deleted, and contains the R299S and R314S mutations in the hBMP-7 mature form domain.
  • Another mutant comprises the human BMP-2 (hBMP-2) secretory signal peptide instead of the native hBMP-7 secretory signal peptide, the hBMP-2 prodomain instead of the native hBMP-7 prodomain, and the R299S and R314S mutations in the hBMP-7 mature form domain.
  • Another mutant comprises the hBMP-2 secretory signal peptide instead of the native hBMP-7 secretory signal peptide, hBMP-2 prodomain instead of the native hBMP-7 prodomain, and the R299S, R314S, R421E, N422D, and R426E mutations in the hBMP-7 mature form domain.
  • These hBMP-7 variant peptide chain mutants were designed, in part, to facilitate improved secretion, proteolytic processing and expression of hBMP-7.
  • Each individual mutation described herein such as point mutations, deletions, or domain replacements can be used alone or in combination to produce the peptide chains of the invention.
  • the mutations described here may also be combined to generate additional variant BMP-7 peptide chains having modified properties corresponding, in part, to the various individual mutations described herein.
  • Nucleic acids encoding such additional variant peptide chains may be generated using standard in vitro or in vivo methods, or combinations of such methods, well known in the art.
  • the peptide chains of the invention may also be post-translationally modified by the addition of one or more covalent modifications such as, for example, the addition of polyethylene glycol to the amino terminus or other portions of the peptide chains of the invention.
  • the signal peptide and prodomain sequences of the variant peptides of the invention may be replaced with functionally equivalent amino acid sequences.
  • Functional equivalents of the point mutations described here may be generated by replacing the amino acid residue at the site of a particular point mutation with a different amino acid residue.
  • variant peptide chains comprising mutated mature domain peptide chains alone and the nucleic acids encoding them are also within the scope of the invention.
  • One aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 4.
  • the peptide chain of SEQ ID NO: 4 was derived from the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S the R314S mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 6.
  • the peptide chain of SEQ ID NO: 6 was derived from the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the ⁇ S293-R299, and R314S mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 8.
  • the peptide chain of SEQ ID NO: 8 was derived from the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the ⁇ S293-M314 mutation.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 10.
  • the peptide chain of SEQ ID NO: 10 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the ⁇ S293-M315 mutation.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 12.
  • the peptide chain of SEQ ID NO: 12 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and L407K mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 14.
  • the peptide chain of SEQ ID NO: 14 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and F409K mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 16.
  • the peptide chain of SEQ ID NO: 16 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and L417R mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 18.
  • the peptide chain of SEQ ID NO: 18 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and L382K mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 20.
  • the peptide chain of SEQ ID NO: 20 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and L382N mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 22.
  • the peptide chain of SEQ ID NO: 22 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and V383K mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 24.
  • the peptide chain of SEQ ID NO: 24 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and I386R mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 26.
  • the peptide chain of SEQ ID NO: 26 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and I386N mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 28.
  • the peptide chain of SEQ ID NO: 28 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, V383K, L407K, and F409K mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 30.
  • the peptide chain of SEQ ID NO: 30 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, and W347D mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 32.
  • the peptide chain of SEQ ID NO: 32 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the R299S, R314S, R421E, N422D and R426E mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 34.
  • the peptide chain of SEQ ID NO: 34 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2 and contains the S293C, R299S, and R314S mutations.
  • the invention provides an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 34 further comprising at least one polyethylene glycol molecule.
  • a polyethylene glycol residue may be covalently linked to C293 of SEQ ID NO: 34 for example.
  • C293 is expected to be the amino terminal residue in the mature form of SEQ ID NO: 34 resulting from proteolytic processing.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 36.
  • the peptide chain of SEQ ID NO: 36 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2.
  • the peptide chain of SEQ ID NO: 36 comprises the hBMP-7 signal peptide (residues Ml to A29 of SEQ ID NO: 2) and prodomain alone (residues D30 to R292 of SEQ ID NO: 20); the hBMP-7 mature form domain (residues S293 to H431 of SEQ ID NO: 2) has been deleted.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 38.
  • the peptide chain of SEQ ID NO: 38 was derived, in part, from the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2.
  • the peptide chain of SEQ ID NO: 38 comprises a human growth hormone signal peptide (residues Ml to A26 of SEQ ID NO: 38) , lacks the hBMP-7 prodomain, and contains the R299S and R314S mutations in the hBMP-7 mature form domain.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 40.
  • the peptide chain of SEQ ID NO: 40 was derived, in part, from the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2.
  • the peptide chain of SEQ ID NO: 40 comprises the hBMP-2 secretory signal peptide instead of the native hBMP-7 secretory signal peptide, hBMP-2 prodomain instead of the native hBMP-7 prodomain, and the R299S and R314S mutations in the hBMP-7 mature form domain.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 42.
  • the peptide chain of SEQ ID NO: 42 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2.
  • the peptide chain of SEQ ID NO: 42 contains the H287R, R299S, R314S, R421E, N422D, and R426E mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 44.
  • the peptide chain of SEQ ID NO: 44 was derived, in part, from the wild-type hBMP-7 precursor peptide chain of SEQ ID NO: 2.
  • the peptide chain of SEQ ID NO: 44 comprises the hBMP-2 secretory signal peptide instead of the native hBMP-7 secretory signal peptide, hBMP-2 prodomain instead of the native hBMP-7 prodomain, and the R299S, R314S, R421E, N422D, and R426E mutations in the hBMP-7 mature form domain.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 46.
  • the peptide chain of SEQ ID NO: 46 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2.
  • the peptide chain of SEQ ID NO: 46 contains the H287T, R299S, and R314S mutations.
  • Another aspect of the invention is an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 48.
  • the peptide chain of SEQ ID NO: 48 was derived from the wild- type hBMP-7 precursor peptide chain of SEQ ID NO: 2.
  • the peptide chain of SEQ ID NO: 48 contains the H287R, R299S, and R314S mutations.
  • One embodiment of the invention is an isolated nucleic acid comprising a nucleic acid sequence encoding a peptide chain of the invention.
  • nucleic acids may be generated using standard in vitro or in vivo methods, or combinations of such methods, well known in the art.
  • nucleic acids may comprise alternative codons encoding the amino acids of the peptide chains of the invention or organism optimized codons encoding the amino acids of the peptide chains of the invention.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 3.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 5.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 7.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 9. Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 11.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 13.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 15.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 17.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 19.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 21.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 23.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 25.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 27.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 29.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 31.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 33.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 35.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 37.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 39.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 41.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 43.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 45.
  • Another aspect of the invention is an isolated nucleic acid comprising the nucleic acid sequence shown in SEQ ID NO: 47.
  • Another embodiment of the invention is a method of inhibiting TGF- ⁇ induced cell proliferation comprising providing a peptide chain of the invention to a cell.
  • the peptide chains of the invention may be provided to cells that are, for example, eukaryotic cells.
  • the peptide chains of the invention can be administered by any technique that provides such molecules to a cell.
  • a peptide chain can be provided to a cell in vitro by, for example, supplementing the culture medium with the peptide chain or a nucleic acid chain encoding the peptide chain.
  • Peptide chains may also be provided to a cell by transfecting a nucleic acid chain encoding the peptide chain into the cell.
  • a peptide chain may be provided to a cell in vivo by, for example, intravenous injection of the peptide chain or a nucleic acid encoding the peptide chain into an animal or tissue.
  • a cell in vivo by, for example, intravenous injection of the peptide chain or a nucleic acid encoding the peptide chain into an animal or tissue.
  • Those skilled in the art will recognize other means for administering the peptide chains of the invention to a cell in vitro or in vivo. Such means also include those modes for delivery of an agent to a host that are discussed below.
  • Another embodiment of the invention is a vector comprising at least one nucleic acid of the invention.
  • Such vectors permit a nucleic acid of the invention to be introduced into a cell, animal or other nucleic acid replication system and expression systems, such as an in vitro transcription and translation system.
  • a vector of the invention may comprise portions of a transposon, plasmid, virus, or chromosome that, alone or when combined, permit a nucleic acid of the invention to be introduced into a cell or other system.
  • a wide variety of such vectors are well known to those skilled in the art.
  • Another embodiment of the invention is a host cell comprising a vector of the invention.
  • Such host cells may be eukaryotic cells, bacterial cells, plant cells or archeal cells.
  • Exemplary eukaryotic cells may be of mammalian, insect, avian or other animal origins.
  • An exemplary mammalian eukaryotic cell line is the HEK-293 (American Type Culture Collection, Manassas, VA; ATCC® Number: CRL-1573TM) cell line.
  • Other useful cell lines include those derived from Chinese Hamster Ovary (CHO) cells such as CHO-Kl (ATCC® Number: CRL-61TM) and rat osteosarcoma (ROS) cells such as ROS 27/2.8 cells.
  • Mammalian eukaryotic cells also include immortalized cell lines such as hybridomas or myeloma cell lines such as SP2/0 (ATCC® Number: CRL-1581TM) , NSO (European Collection of Cell Cultures (ECACC),
  • Another embodiment of the invention is a method of making a peptide chain comprising culturing a host cell of the invention and recovering the peptide chain produced by the host cell .
  • Standard cell culture and enzymology methods well known in the art may be used to culture a host cell of the invention and to recover peptide chains produced by such host cells.
  • Another embodiment of the invention is a method of making a peptide chain comprising expressing an isolated peptide chain comprising the amino acid sequence shown in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 42 in an expression system and recovering a peptide chain wherein the peptide chain is capable of either increasing alkaline phosphatase activity in ROS 17/2.8 cells relative to negative control ROS 17/2.8 cells that did not receive the peptide chain or increasing the number of viable VEPT cells relative to negative control VEPT cells that did not receive the peptide chain.
  • Expression systems useful in the method of the invention may be, for example, an in vitro coupled transcription and translation system, or a cell or other expression system, such as an animal or plant.
  • hBMP-7 mature form activity can be detected by assaying for increased alkaline phosphatase activity in rat osteosarcoma 17/2.8 (ROS 17/2.8) cells treated with the mature form of hBMP-7 relative to untreated control ROS 17/2.8 cells.
  • ROS 17/2.8 rat osteosarcoma 17/2.8
  • hBMP-7 has hBMP-7 activity.
  • Alkaline phosphatase based hBMP-7 assays using ROS 17/2.8 cells can be performed using standard cell culture and enzymology methods well known in the art such as, for example, those described by Maliakal et al . , Growth Factors. 112 (3) : 227-234 (1994).
  • hBMP-7 mature form activity can also be detected by assaying for increased numbers of viable VEPT cells after treatment with the mature form of hBMP-7 relative to untreated negative control VEPT cells.
  • a peptide chain capable of increasing the numbers of viable VEPT cells in a population has hBMP-7 activity.
  • Cell viability based hBMP-7 assays using ROS 17/2.8 cells can be performed using standard cell culture and enzymology methods well known in the art. Those skilled in the art will also recognize that such assays for hBMP-7 activity may also be used to confirm the biological activity and effect of the compositions and methods of the invention.
  • Another embodiment of the invention is a method of treatment comprising the steps of identifying an animal with an hBMP-7 responsive condition; and administering the peptide chain of the invention to the animal in an amount sufficient to attenuate the pathological condition.
  • hBMP-7 activity responsive pathological conditions include, for example, myelofibrosis, idiopathic pulmonary fibrosis, renal osteodystrophy, diabetic nephropathy, chronic obstructive pulmonary disorder (COPD), and osteoarthritis.
  • the methods of treatment of the invention may be used to treat an animal patient belonging to any classification.
  • animals include mammals such as humans, rodents, dogs, cats and farm animals and other animal classes such as birds, reptiles and fish.
  • the mode of administration for therapeutic use of the peptide chains of the invention may be any suitable route that delivers the peptide chain to the host.
  • the peptide chains and nucleic acid chains of the invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly, intradermally, intravenously or intranasally .
  • Peptide chains and nucleic acids of the invention may be prepared as pharmaceutical compositions containing an effective amount of the peptide chain or nucleic acid as an active ingredient in a pharmaceutically acceptable carrier.
  • An aqueous suspension or solution containing the peptide chain or nucleic acid, preferably buffered at physiological pH, in a form ready for injection is preferred.
  • compositions for parenteral administration will commonly comprise a solution of the antagonist of the invention or a cocktail thereof dissolved in an pharmaceutically acceptable carrier, preferably an aqueous carrier.
  • an aqueous carrier e.g. 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter. These solutions may be sterilized by conventional, well-known sterilization techniques (e.g., filtration).
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, etc.
  • concentration of the peptide chains or nucleic acid chains of the invention in such pharmaceutical formulation can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of administration selected.
  • a pharmaceutical composition for intramuscular injection could be prepared to contain 1 mL sterile buffered water, and between about 1 ng to about 100 mg, e.g. about 50 ng to about 30 mg or more preferably, about 5 mg to about 25 mg, of a peptide chain or nucleic acid of the invention.
  • a pharmaceutical composition of the invention for intravenous infusion could be made up to contain about 250 ml of sterile
  • Ringer's solution and about 1 mg to about 30 mg and preferably 5 mg to about 25 mg of an antagonist of the invention.
  • Actual methods for preparing parenterally administrable compositions are well known and are described in more detail in, for example, "Remington's Pharmaceutical Science", 15th ed. , Mack Publishing Company, Easton, PA.
  • the peptide chains and nucleic acids of the invention when in a pharmaceutical preparation, can be present in unit dose forms.
  • the appropriate therapeutically effective dose can be determined readily by those of skill in the art. A determined dose may, if necessary, be repeated at appropriate time intervals selected as appropriate by a physician during the treatment period.
  • the peptide chains or nucleic acids of the invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional protein and immunoglobulin preparations and art-known lyophilization and reconstitution techniques can be employed.
  • Plasmid DNAs hBMP-7 variant proteins were recombinantly expressed in mammalian HEK-293 cells transiently transfected with plasmid
  • HEK-293E cells (Invitrogen, Carlsbad, CA) were propagated using standard culture conditions and methods. Cells were transiently transfected with p3105, p3106, p3107 and p3108 using standard transfection methods. HEK-293E cells were also transiently transfected with p3104 as a control.
  • the p3104 control vector contains a cDNA (SEQ ID NO: 1) encoding the wild-type hBMP-7 precursor protein (SEQ ID NO: 2) .
  • the p3105 vector contains a cDNA (SEQ ID NO: 3) encoding the R299S/R314S hBMP-7 variant protein (SEQ ID NO: 4) .
  • the p3106 vector contains a cDNA (SEQ ID NO: 5) encoding the ⁇ S293- R299/R314S hBMP-7 variant protein (SEQ ID NO: 6) .
  • the p3107 vector contains a cDNA (SEQ ID NO: 7) encoding the ⁇ S293-R314 hBMP-7 variant protein (SEQ ID NO: 8) .
  • the p3108 vector contains a cDNA (SEQ ID NO: 9) encoding the ⁇ S293-M315 hBMP-7 variant protein (SEQ ID NO: 10) .
  • the wild-type or variant hBMP-7 cDNA is fused in frame at its 3' end to a cDNA encoding a hexahistidine tag. Consequently, the proteins expressed by these vectors are all hexahistidine tagged at their carboxy termini.
  • the ELISA data indicates that all hBMP-7 variants were expressed in mammalian HEK-293 cells from the transiently transfected vector DNAs.
  • N-terminal sequencing analysis using standard methods demonstrated that S293 forms the amino terminus of the proteolytically processed mature form of hBMP-7 produced by in vivo expression of SEQ ID NO: 2 from p3104.
  • S293 was also found to form the amino terminus of the proteolytically processed form of hBMP-7 produced by in vivo expression of SEQ ID NO: 4 from p3105.
  • hBMP-7 variant proteins were recombinantly expressed in mammalian CHO-Kl cells transiently transfected with plasmid DNAs encoding each variant (Fig. 1) .
  • CHO-Kl cells ATCC® Number: CRL-9618TM
  • Cells were transiently transfected with p3341, p3392, p3268, or p3470 and p3199 using standard transfection methods.
  • CHO-Kl cells were also transiently transfected with the pEMPTY negative control vector which lacked a cDNA insert encoding a hBMP-7 variant.
  • the p3341 positive control vector contains a cDNA (SEQ ID NO: 1) encoding the wild-type hBMP-7 precursor protein (SEQ ID NO: 2) .
  • the p3392 vector contains a cDNA (SEQ ID NO: 41) encoding an hBMP-7 variant protein (SEQ ID NO: 42) that comprises the native hBMP-7 secretory signal peptide, an hBMP-7 prodomain comprising an H287R mutation, and the R299S, R314S, R421E, N422D, and R426E mutations in the hBMP-7 mature form domain.
  • the p3268 vector contains a cDNA (SEQ ID NO: 39) encoding an hBMP-7 variant protein (SEQ ID NO: 40) that comprises the hBMP-2 secretory signal peptide instead of the native hBMP-7 secretory signal peptide, the hBMP-2 prodomain instead of the native hBMP-7 prodomain, and the R299S and R314S mutations in the hBMP-7 mature form domain.
  • the p3470 vector contains a cDNA (SEQ ID NO: 43) encoding an hBMP-7 variant protein (SEQ ID NO: 44) that comprises the hBMP-2 secretory signal peptide instead of the native hBMP-7 secretory signal peptide, the hBMP-2 prodomain instead of the native hBMP-7 prodomain, and the R299S, R314S, R421E, N422D and R426E mutations in the hBMP-7 mature form domain.
  • the p3199 vector encodes, and constituatively expresses, the paired dibasic amino acid-cleaving protease enzyme (PACE) furin.
  • PACE paired dibasic amino acid-cleaving protease enzyme
  • Furin is the protease required for the proteolytic processing events needed to produce the mature form of hBMP-7 from hBMP-7 precursor protein.
  • p3199 was transiently co-transfected with the vectors encoding the hBMP-7 variants encoded by p3341, p3392, p3268, or p3470 to facilitate the expression of mature, proteolytically processed hBMP-7 variant proteins.
  • Cell culture supernatant was collected after transfection and hBMP-7 variant proteins were purified from the supernatant using standard immunoaffinity chromatography methods.
  • a monoclonal antibody that specifically binds the mature form of hBMP-7 (residues 293 to 431 of SEQ ID NO: 2) was conjugated to an insoluble resin and the resulting mAb- conjugated resin was used to perform immunoaffinity chromatography using standard methods.
  • the Sepharose 4B resin (Amersham Biosciences, Piscataway, NJ) was activated by cyanogen bromide (CNBr) and the anti-BMP-7 mAb (1B12) was conjugated to the resin through reactive amine groups.
  • a standard sandwich-type ELISA (Quantikine DBP700, R&D Systems, Minneapolis, MN) specific for hBMP-7 was then performed on the resulting samples (Fig. 3) according to the manufacturers instructions. Positive control ELISAs were also performed on purified wild-type hBMP-7 samples to generate a calibration curve (data not shown) . Assay data is expressed in ng of BMP-7 per ml of cell culture supernatant (Fig. 3; Y-axis) .
  • the hBMP-7 variant peptide chain encoded by p3392 was expressed at relatively high levels (Fig 3.) in CHO-Kl cells and was properly processed based on SDS-PAGE and Western blot analyses.
  • the peptide chain encoded by p3392 is an hBMP-7 variant protein (SEQ ID NO: 42) that comprises the native hBMP-7 secretory signal peptide, an hBMP-7 prodomain comprising an
  • H287R mutation and the R299S, R314S, R421E, N422D, and R426E mutations in the hBMP-7 mature form domain.
  • the hBMP-7 variant peptide (SEQ ID NO: 42) encoded by p3392 was expressed by transient transfection of CHO-Kl cells with p3392 using standard transfection and cell culture techniques. Cell culture supernatants were prepared as described in Example 2 above.
  • the hBMP-7 variant protein expressed (SEQ ID NO: 42) by p3392 was then immunoaffinity purified by immunoaffinity chromatography as described in Example 2 above. Supernatant samples were loaded onto chromatography columns and eluted using 100 mM glycine buffer pH 2.5 - acid elution, or ⁇ gentle buffer' elution (Pierce Biotechnology, Rockford IL) - neutral elution.
  • SDS-PAGE and Western blot analysis further indicated the presence of fully processed 15 kDa and 17 kDa mature forms the hBMP-7 variant protein (SEQ ID NO: 42) encoded by p3392 and a 48 kDa form corresponding to the unprocessed form of this hBMP-7 variant.
  • the 15 kDa and 17 kDa forms are believed to be the product of differential post- translational modifications such as glycosylation.
  • the hBMP-7 variant peptide (SEQ ID NO: 42) encoded by p3392 was expressed at relatively high levels (Fig 3.) and was properly processed based on SDS-PAGE and Western blot analyses. This particular hBMP-7 variant protein was then selected for further bioactivity assay analyses.
  • the hBMP-7 variant protein 3392 (SEQ ID NO: 42) is biologically active when recombinantly expressed in CHO-Kl cells (Fig. 4) and assayed in an osteosarcoma cell based assay system. This variant protein also has biological activity comparable to that of wild-type hBMP-7 provided at an identical concentration (Fig. 4) .
  • hBMP-7 mature form biological activity was assayed using a rat osteosarcoma 17/2.8 cell alkaline phosphatase induction assay.
  • Biologically active hBMP-7 induces alkaline phosphatase expression by ROS 17/2.8 cells.
  • ROS 17/2.8 cells are capable of causing bone formation by osteogenesis and increased alkaline phosphatase activity is a hallmark of the induction of osteogenesis .
  • ROS 17/2.8 cells were seeded at a density of 30,000 cells per well in a 96 well plate and cultured overnight using standard methods. Recombinant purified mature form hBMP-7 was then provided to the cells as a positive control. Cells were also provided with recombinantly expressed hBMP-7 variant protein 3392 eluted from the immunoaffinity column with an acidic buffer or a neutral buffer. hBMP-7 variant protein 3392 was recombinantly expressed in CHO-Kl cells and purified by immunoaffinity chromatography as described above (Example 3) .
  • hBMP-7 protein was provided to cells in a quantity sufficient to produce the final concentration indicated in Fig. 4. Cells were then incubated for two days and cell lysates were prepared. Lysates were assayed for alkaline phosphatase activity using standard methods . These results demonstrate the hBMP-7 variant protein 3392 recombinantly expressed in CHO-Kl cells is biologically active and that this variant protein has biological activity comparable to that of wild-type hBMP-7 provided at an identical concentration (Fig. 4) . These results also indicate hBMP-7 variant protein 3392 (SEQ ID NO: 42) will have the ability to induce bone formation through osteogenesis and have utility in the treatment of conditions were inducing bone formation is desireable. Error bars in Fig. 4 represent the mean +/- standard error. Example 5
  • the hBMP-7 variant protein 3392 (SEQ ID NO: 42) is biologically active when recombinantly expressed in CHO-Kl cells (Fig. 4) and assayed in a kidney cell proliferation based assay system. This variant protein also has biological activity comparable to that of wild-type hBMP-7 provided at an identical concentration (Fig. 4) . hBMP-7 mature form biological activity was assayed using a VEPT cell proliferation assay.
  • VEPT cells (ATCC CRL-2087) are a rabbit kidney proximal tubular epithelium derived, immortalized cell line. Biologically active hBMP-7 induces VEPT cell proliferation.
  • hBMP-7 has been reported to be an antifibrotic capable of maintaining kidney epithelial cell proliferation and antagonizing the accumulation of extracellular matrix (ECM) in the kidney.
  • ECM extracellular matrix
  • Excessive accumulation of extracellular matrix (ECM) in kidney tissues is associated with virtually every type of chronic kidney disease (e.g. renal fibrosis) .
  • VEPT cells were seeded at a density of 2500 cells per well in a 96 well plate and cultured overnight using standard methods. Recombinant purified mature form hBMP-7 was then provided to the cells as a positive control. Cells were also provided with recombinantly expressed hBMP-7 variant protein 3392 eluted from the immunoaffinity column with an acidic buffer or a neutral buffer. hBMP-7 variant protein 3392 was recombinantly expressed in CHO-Kl cells and purified by immunoaffinity chromatography as described above (Example 3) . hBMP-7 protein was provided to cells in a quantity sufficient to produced the final concentration indicated in Fig. 5. Cells were then incubated for four days and the CellTiter-Glo® luminescent cell viability assay kit (Promega Inc., Madison, WI) was used to detect proliferating cells as directed by the manufacturer .
  • CellTiter-Glo® luminescent cell viability assay kit Promega Inc.
  • hBMP-7 variant protein 3392 recombinantly expressed in CHO-Kl cells is biologically active and that this variant protein has biological activity comparable to that of wild-type hBMP-7 provided at an identical concentration (Fig. 5) .
  • hBMP-7 variant protein 3392 SEQ ID NO: 42
  • Error bars in Fig. 5 represent the mean +/- standard error.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des chaînes de peptides de variantes de hBMP-7 (Human Bone Morphogenic Protein), des acides nucléiques codant ces chaînes de peptides, ainsi que des procédés de fabrication et d'utilisation de ces chaînes de peptides.
PCT/US2007/070584 2006-07-27 2007-06-07 Compositions à base de variantes de bmp-7, procédés et utilisations WO2008014054A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009521874A JP2009544325A (ja) 2006-07-27 2007-06-07 Ｂｍｐ−７変異体組成物、方法および使用
EP07798210A EP2056852A4 (fr) 2006-07-27 2007-06-07 Compositions à base de variantes de bmp-7, procédés et utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82053806P 2006-07-27 2006-07-27
US60/820,538 2006-07-27

Publications (2)

Publication Number Publication Date
WO2008014054A2 true WO2008014054A2 (fr) 2008-01-31
WO2008014054A3 WO2008014054A3 (fr) 2009-04-09

Family

ID=38982164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/070584 WO2008014054A2 (fr) 2006-07-27 2007-06-07 Compositions à base de variantes de bmp-7, procédés et utilisations

Country Status (3)

Country Link
EP (1) EP2056852A4 (fr)
JP (1) JP2009544325A (fr)
WO (1) WO2008014054A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101279145B1 (ko) * 2012-08-10 2013-06-26 주식회사 셀루메드 활성형 ｂｍｐ7의 생산율 증가 방법
US11572396B2 (en) 2014-07-10 2023-02-07 Cambridge Enterprise Limited Therapeutic use of bone morphogenetic proteins

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
IT1259042B (it) * 1992-01-27 1996-03-11 Mini Ricerca Scient Tecnolog Preparazione di vettori di espressione per la sintesi del polipeptide chiamato fattore osteogenetico op-1 in cellule eucariotiche di spodoptera frugiperda via infezione con baculovirus ricombinante
KR950702627A (ko) * 1992-07-31 1995-07-29 찰스 엠. 코헨 모르포겐 단백질의 가용성 복합체 및 그의 조성물(Morphogenic Protein Soluble Complex and Composition Thereof)
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
JP5100662B2 (ja) * 2005-12-22 2012-12-19 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2056852A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101279145B1 (ko) * 2012-08-10 2013-06-26 주식회사 셀루메드 활성형 ｂｍｐ7의 생산율 증가 방법
US11572396B2 (en) 2014-07-10 2023-02-07 Cambridge Enterprise Limited Therapeutic use of bone morphogenetic proteins

Also Published As

Publication number Publication date
EP2056852A4 (fr) 2010-01-13
JP2009544325A (ja) 2009-12-17
EP2056852A2 (fr) 2009-05-13
WO2008014054A3 (fr) 2009-04-09

Similar Documents

Publication Publication Date Title
EP1978994B1 (fr) Compositions à base de variantes de bmp-7, procédés et utilisations
US9956264B2 (en) MIC-1 fusion proteins and uses thereof
EP2858662B1 (fr) Proteines facteur de croissance fibroblastes 21
JP6060167B2 (ja) 線維芽細胞増殖因子２１変異体
EP2859014B1 (fr) Variants du facteur de croissance 21 du fibroblaste
WO2016106229A1 (fr) Procédés d'amélioration du rendement dans la production de protéines recombinées
US20170334971A1 (en) Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
WO2008014054A2 (fr) Compositions à base de variantes de bmp-7, procédés et utilisations
US7659250B2 (en) BMP-7 variant compositions, methods and uses
US20220144903A1 (en) Recombinant ccn domain proteins and fusion proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07798210

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009521874

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2007798210

Country of ref document: EP